Genetic medicine outfit Ensoma is halving its workforce, with most of the impacted roles related to platform research ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics ...

While the board considers which path to take, it is implementing various “cost-containment and cash conservation measures,” ...

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but as the company’s CEO sees it—it’s never about the price tag. | Novartis may have signed off on the second ...

Korea’s Celltrion is continuing to think bigger than biosmilars, this time securing the option to use TriOar’s antibody ...

Precise Bio has reported the first successful human implantation of its 3D-printed cornea implant, constructed of functional ...

As the biopharma world predominantly invests in late-stage assets, Eli Lilly is prioritizing early science with the opening ...

After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...